#Biotech #Podcast - Sigyn Therapeutics (OTC:$SIGY) Talks about Treatment
of #Cytokine Storm Syndrome- leading cause of
death related to severe #COVID19 infections and sepsis; @Sigyn_inc
Point Roberts WA, Delta BC, January 26, 2021 -
Investorideas.com, a
global news source and leading retail investor and trader resource issues a new
CEO interview for the Podcast Corner. In today’s
special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) Chairman and CEO, Jim Joyce.
Previously, Mr. Joyce was the founder and
former Chairman and CEO of Aethlon Medical, Inc. (NASDAQ:
AEMD)
Listen to today’s Podcast:
https://www.investorideas.com/Audio/Podcasts/2021/012021SIGY-CEO-Interview.mp3
Read this in full at https://www.investorideas.com/news/2021/biotech/01261SIGY-Cytokine-Storm-Syndrome.asp
Listen
to Investor Ideas podcasts on Spotify
Mr. Joyce discusses Sigyn
Therapeutics vision for addressing life-threatening inflammatory conditions
that are precipitated by Cytokine Storm Syndrome stating, “Cytokine Storm Syndrome is a dis-regulated immune response
that results in the overproduction of inflammatory cytokines that can induce organ failure and
cause death. It can be triggered by a wide range of infectious conditions and
is a leading cause of death related to severe COVID-19 infections. It also underlies sepsis, which is the number
one cause of in-hospital deaths worldwide and an annual market opportunity that
exceeds $20 billion.” Mr Joyce added
that: “Cytokine Storm Syndrome can also be triggered by non-infectious disease
conditions such as an adverse response to drug therapies including emerging
cancer immunotherapies.”
Mr. Joyce further discussed how
the limitations of single-target drugs have created an increased interest in
extracorporeal blood purification technologies that can address a
broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are
limited to a single Cytokine target.
Continued: “We really see
two pioneering devices and they happen to be associated with public companies.
One is the CytoSorb device from CytoSorbents Corporation (NASDAQ:
CTSO)
which has a market value of approximately $400 million. This device is designed
to reduce the presence of a broad-spectrum of inflammatory cytokines from
circulation.”
Continued: “The other
device is the Toraymyxin Device which is a product of Toray Industries, Inc. (3402.T) based in
Japan. This is one of about several
products from Toray that drives a market value of about $10 billion. The
Toraymyxin product eliminates circulating endotoxins, which is a
potent activator of the cytokine storm.”
Continued: “However, it
does not address inflammatory Cytokines. Inversely, CytoSorb addresses
inflammatory Cytokines but
doesn't address endotoxin.
So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory
Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory
Cytokine cargos throughout the circulatory system (OTCMarkets:
SIGY).”
Sigyn
Therapeutics is a development-stage therapeutic technology company
headquartered in San Diego, California, USA. Their focus is directed toward a
significant unmet need in global health; the treatment of life-threatening
inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their
mission is to save lives.
Sigyn
Therapy™ is a novel blood purification technology designed to mitigate cytokine
storm syndrome through the broad-spectrum depletion of inflammatory targets
from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which
is the most common cause of in-hospital deaths and claims more lives each year
than all forms of cancer combined. Virus induced cytokine storm (VICS) is
associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19)
deaths. Other therapeutic opportunities include, but are not limited to
bacteria induced cytokine storm (BICS), acute respiratory distress syndrome
(ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
Joyce also discusses his previous leadership
role at Aethlon Medical, Inc. (NASDAQ:
AEMD) where he oversaw the development of the
Hemopurifier to treat life-threatening viral infections and address
tumor-derived exosomes in cancer patients as a great experience prior to
founding Sigyn Therapeutics, Inc.
To
learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party
news, research and original financial content. Learn about investing in stocks
and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports
biotech, water, renewable energy and more. Investor Idea’s original branded
content includes the following podcasts and columns : Crypto
Corner , Play by Play sports and
stock news column, Investor Ideas Potcasts Cannabis
News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye
.
The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com,
iHeartRadio and Google Play Music.
Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/
Investors can trade these stocks and other
ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video, interviews
and articles. Original content created by investorideas is protected by
copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more
about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please
read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact
Investorideas.com
800-665-0411
BiotechIndustryStocks.com -
investing ideas in biotechnology stocks, medical technology and life sciences
Like
Biotech Stocks? View our Biotech Stocks Directory
Get News Alerts on Biotech Stocks
No comments:
Post a Comment